CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
VIA-2291 +1 moredrug
Likely dose
VIA-2291 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00552188
NCT00552188Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

Tallikut Pharmaceuticals, Inc.·interventional·Posted Nov 1, 2007·Updated Aug 9, 2013

In Brief

A Phase 2 clinical trial evaluating VIA-2291 and Placebo for Acute Coronary Syndrome. Completed, enrolled 52 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesUnited States
CollaboratorsMassachusetts General Hospital, Icahn School of Medicine at Mount Sinai, University of Massachusetts, Worcester, Winthrop University Hospital, Montreal Heart Institute

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 1, 2007
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.7 years ago

Interventions

VIA-2291drug

100 mg, oral dosing, 1 time daily for 24 weeks

Placebodrug

oral dosing, 1 time daily for 24 weeks